Creative Realities Signs Exclusive Agreement with Toyota/Lexus Canada to Power the Dealership Digital Experience
results
View All ->
Intuitive Machines Reports Third Quarter 2026 Financial Results; Reports Record Financials Across The Board - Revenue, Profitability, Positive Cash Flow, and Backlog
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), leading space technology and infrastructure services company, today announced its financial results for the third quarter ended September 30, 2026. Intuitive Machines CEO Steve Altemus said, “In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the stat
Nexxen Reports Record Third Quarter 2026 Financial Results
Delivered record Q3 Contribution ex-TAC and programmatic revenue, highlighted by continued enterprise momentum and 39% year-over-year CTV revenue growth, alongside a 22% year-over-year increase in Adjusted EBITDA Reaffirmed full-year 2026 Contribution ex-TAC, programmatic revenue and Adjusted EBITDA guidance following three top line guidance increases earlier this year Extended $40 million share repurchase program authorization and currently expects to resume share repurchases in the second half
newsSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026 Completed underwritten offering of Series A Common
quarter
View All ->Intuitive Machines Reports Third Quarter 2026 Financial Results; Reports Record Financials Across The Board - Revenue, Profitability, Positive Cash Flow, and Backlog
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), leading space technology and infrastructure services company, today announced its financial results for the third quarter ended September 30, 2026. Intuitive Machines CEO Steve Altemus said, “In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the stat
Nexxen Reports Record Third Quarter 2026 Financial Results
Delivered record Q3 Contribution ex-TAC and programmatic revenue, highlighted by continued enterprise momentum and 39% year-over-year CTV revenue growth, alongside a 22% year-over-year increase in Adjusted EBITDA Reaffirmed full-year 2026 Contribution ex-TAC, programmatic revenue and Adjusted EBITDA guidance following three top line guidance increases earlier this year Extended $40 million share repurchase program authorization and currently expects to resume share repurchases in the second half
newsSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026 Completed underwritten offering of Series A Common
third
View All ->Intuitive Machines Reports Third Quarter 2026 Financial Results; Reports Record Financials Across The Board - Revenue, Profitability, Positive Cash Flow, and Backlog
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), leading space technology and infrastructure services company, today announced its financial results for the third quarter ended September 30, 2026. Intuitive Machines CEO Steve Altemus said, “In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the stat
Nexxen Reports Record Third Quarter 2026 Financial Results
Delivered record Q3 Contribution ex-TAC and programmatic revenue, highlighted by continued enterprise momentum and 39% year-over-year CTV revenue growth, alongside a 22% year-over-year increase in Adjusted EBITDA Reaffirmed full-year 2026 Contribution ex-TAC, programmatic revenue and Adjusted EBITDA guidance following three top line guidance increases earlier this year Extended $40 million share repurchase program authorization and currently expects to resume share repurchases in the second half
newsSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026 Completed underwritten offering of Series A Common
reports
View All ->Intuitive Machines Reports Third Quarter 2026 Financial Results; Reports Record Financials Across The Board - Revenue, Profitability, Positive Cash Flow, and Backlog
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), leading space technology and infrastructure services company, today announced its financial results for the third quarter ended September 30, 2026. Intuitive Machines CEO Steve Altemus said, “In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the stat
Nexxen Reports Record Third Quarter 2026 Financial Results
Delivered record Q3 Contribution ex-TAC and programmatic revenue, highlighted by continued enterprise momentum and 39% year-over-year CTV revenue growth, alongside a 22% year-over-year increase in Adjusted EBITDA Reaffirmed full-year 2026 Contribution ex-TAC, programmatic revenue and Adjusted EBITDA guidance following three top line guidance increases earlier this year Extended $40 million share repurchase program authorization and currently expects to resume share repurchases in the second half
newsSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026 Completed underwritten offering of Series A Common
financial
View All ->Intuitive Machines Reports Third Quarter 2026 Financial Results; Reports Record Financials Across The Board - Revenue, Profitability, Positive Cash Flow, and Backlog
HOUSTON, Nov. 12, 2026 (GLOBE NEWSWIRE) -- Intuitive Machines, Inc. (Nasdaq: LUNR, “Intuitive Machines,” or the “Company”), leading space technology and infrastructure services company, today announced its financial results for the third quarter ended September 30, 2026. Intuitive Machines CEO Steve Altemus said, “In the third quarter, we delivered record financial performance across the board. These results are an important proof point in our transformation from a company that advanced the stat
Nexxen Reports Record Third Quarter 2026 Financial Results
Delivered record Q3 Contribution ex-TAC and programmatic revenue, highlighted by continued enterprise momentum and 39% year-over-year CTV revenue growth, alongside a 22% year-over-year increase in Adjusted EBITDA Reaffirmed full-year 2026 Contribution ex-TAC, programmatic revenue and Adjusted EBITDA guidance following three top line guidance increases earlier this year Extended $40 million share repurchase program authorization and currently expects to resume share repurchases in the second half
newsSagimet Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Updates
Registrational U.S. AURORA Phase 3 clinical trial underway for denifanstat in moderate to severe acne, with topline data anticipated in the second half of 2027 Positive denifanstat Phase 3 clinical trial results in China from license partner Ascletis, and continued improvement and sustained efficacy across all efficacy endpoints through 52 weeks in the open-label extension clinical trial, presented at EADV 2026 and Fall Clinical Dermatology 2026 Completed underwritten offering of Series A Common
Magazine Focus
The New Growth Playbook: Building Businesses for Sustainable Expansion
Growth is being redefined. Expanding revenue remains important, but businesses are placing greater emphasis on profitability, cash discipline, operational efficiency, customer retention and resilience. This edition explores the changing growth playbook and the foundations required for sustainable expansion. From technology and process design to capital allocation and market reach, it examines how businesses can pursue ambition without allowing complexity, costs or uncontrolled expansion to weaken the enterprise.
For years, growth was often discussed primarily in terms of size, speed and market share. The conversation is becoming more balanced. Strong businesses also need healthy economics, efficient operations and the ability to withstand uncertainty. This edition looks at growth through that wider lens and considers how organizations can expand with greater discipline, clarity and long-term purpose in practice.
The day in focus. Delivered to your inbox.
A concise daily briefing of key stories, insights and developments, selected by our editorial team.
By subscribing, you agree to our Privacy Policy. Unsubscribe at any time.